AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.91 |
Market Cap | 40.72M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.49 |
PE Ratio (ttm) | -0.69 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.3 |
Volume | 22,867 |
Avg. Volume (20D) | 51,932 |
Open | 1.00 |
Previous Close | 0.98 |
Day's Range | 0.91 - 1.12 |
52-Week Range | 0.80 - 4.16 |
Beta | undefined |
About BRNS
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, ...
Analyst Forecast
According to 2 analyst ratings, the average rating for BRNS stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 191.29% from the latest price.